{"product_id":"tbph-swot-analysis","title":"(TBPH) Theravance Biopharma, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidate Every Claim with the Complete Sources File\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Theravance Biopharma, Inc. SWOT Analysis summarizes the company’s business, products, and strategic position, showing strengths, weaknesses, opportunities, and threats in a concise framework; the page includes a real preview\/sample of the analysis so you can judge style and substance. Purchase the full version to receive the complete, ready-to-use SWOT report for research, strategy, or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYUPELRI COPD asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUPELRI gives Theravance Biopharma, Inc. an approved COPD drug and real-world commercial know-how. COPD is a high-volume chronic market, with more than 16 million U.S. adults diagnosed, so the asset supports brand visibility and physician familiarity. It also gives Theravance Biopharma, Inc. a revenue base in respiratory care instead of relying only on pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTRELEGY revenue participation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTRELEGY revenue participation gives Theravance Biopharma exposure to a marketed respiratory brand beyond its own pipeline, with GSK reporting TRELEGY sales above $3.5 billion in 2024. It also spreads risk across two huge airway disease markets: COPD affects about 300 million people worldwide and asthma about 260 million. That scale makes the royalty stream more durable than a single-product niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth America Europe Asia footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. operates across 3 major regions—North America, Europe, and Asia—which gives it more than one path for approvals and sales. That spread lowers reliance on any single market and can cushion region-specific shocks. A wider footprint also helps the Company scale launches and partnerships faster across multiple health systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmpreloxetine Phase III completed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmpreloxetine has completed Phase III in neurogenic orthostatic hypotension, making it one of Theravance Biopharma, Inc.'s most advanced pipeline assets. Late-stage completion lowers clinical risk and can support near-term partnering or filing decisions.\u003c\/p\u003e\n\u003cp\u003eThis strength matters because Phase III data can unlock clearer valuation and deal timing versus earlier-stage assets. It also gives Theravance Biopharma, Inc. a more visible path to monetization if results hold up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase III completed\u003c\/li\u003e\n\u003cli\u003eLate-stage de-risking\u003c\/li\u003e\n\u003cli\u003eSupports partner talks\u003c\/li\u003e\n\u003cli\u003eCan enable filing decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline across JAK fibrosis GI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. has a six-program pipeline across izencitinib, nezulcitinib, inhaled ALK5i, TD-5202, velusetrag, and a selective 5-HT4 agonist, giving it shots in inflammatory bowel disease, lung injury, fibrosis, and motility disorders. That mix spreads risk and creates multiple paths to value if even one or two assets advance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSix programs, four disease areas\u003c\/li\u003e\n\u003cli\u003eExposure to GI, lung, and fibrosis\u003c\/li\u003e\n\u003cli\u003eMore than one value driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheravance’s Commercial Base and Late-Stage Pipeline Boost Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. has two marketed respiratory assets, YUPELRI and TRELEGY revenue participation, which give it real sales exposure and reduce pure pipeline risk. Ampreloxetine has already finished Phase III, and the six-program pipeline adds more shots across GI, lung injury, fibrosis, and motility. That mix gives Company Name multiple paths to value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial base\u003c\/td\u003e\n\u003ctd\u003eYUPELRI; TRELEGY royalty\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage asset\u003c\/td\u003e\n\u003ctd\u003eAmpreloxetine Phase III complete\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline breadth\u003c\/td\u003e\n\u003ctd\u003e6 programs, 4 disease areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Theravance Biopharma, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear, concise SWOT snapshot for Theravance Biopharma, Inc. to speed strategic decisions and reduce analysis overload.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, FDA filings, and financials to speed due diligence and verify Theravance Biopharma claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited marketed portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. has a narrow commercial base, with YUPELRI as the only clearly identified proprietary marketed product in its portfolio as of FY2025. That means 1 product carries most of the company’s marketed revenue risk, unlike larger biopharma peers with multiple approved drugs. This concentration makes earnings more exposed to demand swings, pricing pressure, and any supply or reimbursement setback.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMost assets remain clinical stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMost of Theravance Biopharma, Inc.'s pipeline is still in Phase I, Phase II, or Phase IIb\/III, so revenue is still years away for many programs. Clinical-stage assets have no approval guarantee, and any one trial can fail on efficacy, safety, or timing. That leaves Theravance exposed to development risk across several programs at once, while R\u0026amp;D spending stays tied to assets that have not yet converted into sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmpreloxetine still unapproved\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmpreloxetine is still unapproved, so Theravance Biopharma, Inc. cannot book commercial revenue from it yet. Even after Phase III completion, the asset still needs FDA approval and payer access, and those steps can still fail. That leaves its value uncertain and tied to a binary regulatory outcome, not sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRespiratory concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. still depends heavily on respiratory therapeutics, with YUPELRI and TRELEGY tied to COPD and related lung care in 2025. That narrows the business to one therapy area, so any shift in inhaler pricing, payer access, or class competition can hit revenue fast.\u003c\/p\u003e\n\u003cp\u003eTRELEGY is a multibillion-dollar product for GSK, but Theravance Biopharma, Inc. only captures a royalty stream, not full product economics. That makes the company more exposed to respiratory market swings than a broader biopharma peer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh COPD concentration\u003c\/li\u003e\n\u003cli\u003eRoyalties, not full sales\u003c\/li\u003e\n\u003cli\u003ePricing and access risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-dependent economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheravance Biopharma’s economics still depend on a small partner set, including Pfizer, Viatris, Janssen, Alfasigma, and Takeda, so the company does not keep all upside from its programs. That matters because partner deals usually cap Theravance Biopharma’s share of sales and milestones versus full ownership. It also means launch timing, promotion, and label execution sit partly with others.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower take rate than full ownership\u003c\/li\u003e\n\u003cli\u003eLess control over timing and execution\u003c\/li\u003e\n\u003cli\u003eRevenue tied to partner priorities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheravance’s Revenue Is Too Concentrated for Comfort\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. remains weakly diversified: FY2025 revenue leaned on YUPELRI and partner royalties, while most pipeline assets were still precommercial. That leaves earnings exposed to one product, one therapy area, and FDA or payer setbacks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct concentration\u003c\/td\u003e\n\u003ctd\u003eYUPELRI-led revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003eMostly Phase I-III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner dependence\u003c\/td\u003e\n\u003ctd\u003eRoyalty-heavy model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy focus\u003c\/td\u003e\n\u003ctd\u003eCOPD concentrated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eTheravance Biopharma, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and purchasing unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats tailored to Theravance Biopharma, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIzencitinib multi-indication path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma's izencitinib spans rheumatoid arthritis, myelofibrosis, ulcerative colitis, and Crohn's disease, giving it four shots at success. Ulcerative colitis and Crohn's together affect over 3 million adults in the U.S., while rheumatoid arthritis tops 18 million globally, so one win could lift pipeline value fast. That breadth lowers single-program risk and widens the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmpreloxetine for nOH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmpreloxetine targets neurogenic orthostatic hypotension, a symptom that can affect up to 30% of people with Parkinson’s disease and other autonomic disorders. \u003c\/p\u003e\n\u003cp\u003ePhase III completion would move Theravance Biopharma, Inc. closer to a filing or partnering step, which can de-risk the asset and lift deal value. \u003c\/p\u003e\n\u003cp\u003eIf development stays on track, Ampreloxetine could open a niche neurology market with limited approved options. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNezulcitinib hospitalized lung injury\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNezulcitinib gives Theravance Biopharma a hospital-focused respiratory asset: it is a lung-specific nebulized JAK inhibitor in Phase II, aimed at severe lung injury in hospitalized COVID-19 patients. That niche matters because the inhaled route may concentrate drug in the lungs and support a targeted inpatient use case. If the trial data stay strong, it could add a differentiated option in a high-need, acute-care setting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInhaled ALK5i in IPF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInhaled ALK5i is in Phase I for idiopathic pulmonary fibrosis, a disease that affects about 3 million people worldwide and still has limited treatment choices. If the inhaled antifibrotic shows safety and lung delivery, it could add a new respiratory asset and broaden Theravance Biopharma, Inc.'s pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I ALK5i in IPF\u003c\/li\u003e\n\u003cli\u003eLarge unmet need in fibrosis\u003c\/li\u003e\n\u003cli\u003ePotential pipeline upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTD-5202 and GI motility assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTD-5202 broadens Theravance Biopharma, Inc. beyond respiratory drugs: it is a gut-selective oral JAK3 inhibitor in Phase I for inflammatory intestinal disease, while velusetrag and the selective 5-HT4 agonist target gastrointestinal motility disorders. This creates two shots at GI markets with different biology and reduces reliance on a single therapeutic area. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I TD-5202 in intestinal inflammation\u003c\/li\u003e\n\u003cli\u003eVelusetrag targets motility disorders\u003c\/li\u003e\n\u003cli\u003e5-HT4 agonist adds GI pipeline depth\u003c\/li\u003e\n\u003cli\u003eBroader growth beyond respiratory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheravance’s Pipeline: Multiple Shots at De-Risked Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc.’s biggest upside sits in pipeline de-risking: izencitinib covers ulcerative colitis, Crohn’s, rheumatoid arthritis, and myelofibrosis, while Ampreloxetine could address neurogenic orthostatic hypotension with few approved rivals. Nezulcitinib and inhaled ALK5i add lung-focused shots in acute and fibrotic disease. TD-5202 and motility assets widen the GI base and cut single-therapy risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIzencitinib\u003c\/td\u003e\n\u003ctd\u003e4 indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmpreloxetine\u003c\/td\u003e\n\u003ctd\u003ePhase III value step\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNezulcitinib\u003c\/td\u003e\n\u003ctd\u003eHospital respiratory niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTD-5202\u003c\/td\u003e\n\u003ctd\u003eGI expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJAK safety scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJAK safety scrutiny is a real threat for Theravance Biopharma, Inc. because the class already carries FDA boxed warnings from 2021 for risks like serious infection, cancer, blood clots, and death. Several pipeline assets are JAK or JAK-related, so one adverse signal could hurt more than one program at once and slow prescriber uptake. That can raise trial, label, and commercial risk across the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIzencitinib is in Phase IIb\/III, and ampreloxetine has already finished Phase III, so both assets face the highest-risk part of development. Late-stage programs can still fail on efficacy, safety, or endpoint miss, and one setback can erase years of spend and delay any cash return. For Theravance Biopharma, Inc., that makes each pivotal readout a binary event with outsized valuation risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOPD and IBD competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma faces tough competition in COPD and IBD, where big drug makers have wider sales forces and fuller pipelines. COPD affects about 390 million people worldwide, and IBD impacts more than 7 million, so crowded markets still draw heavy rival spending. That makes it harder for Theravance Biopharma to win share unless it proves clear clinical and commercial differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. faces regulatory risk because FDA review can take 10 months for standard filings and 6 months for priority ones, and novel respiratory or immunology assets can see delays if the agency asks for more data. After approval, payer access can still lag; in the U.S., list prices can face heavy pressure as Medicare price negotiation begins in 2026 for selected high-spend drugs. That can slow uptake and cap long-term margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA timing can slip on new data requests\u003c\/li\u003e\n\u003cli\u003eReimbursement delays can slow launch adoption\u003c\/li\u003e\n\u003cli\u003ePricing cuts can weaken long-run returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner strategy changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheravance Biopharma depends on five key collaborators: Pfizer, Viatris, Janssen, Alfasigma, and Takeda. If one partner shifts priorities, trial timing, filings, or launches can slip, and Theravance cannot fully control that delay. That makes execution risk higher across partnered programs and royalty streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 major partners drive key programs\u003c\/li\u003e\n\u003cli\u003ePartner shifts can slow launches\u003c\/li\u003e\n\u003cli\u003eRisk sits outside direct control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheravance Faces High Pipeline and Safety Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheravance Biopharma, Inc. faces high pipeline risk because izencitinib is still in Phase IIb\/III and ampreloxetine is in late-stage development, where any safety or efficacy miss can wipe out value. JAK-class safety warnings, including the FDA’s 2021 boxed warning, can slow adoption and widen label risk. Partner dependence and crowded COPD and IBD markets add launch and pricing pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJAK safety\u003c\/td\u003e\n\u003ctd\u003eFDA boxed warning, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage assets\u003c\/td\u003e\n\u003ctd\u003ePhase IIb\/III and Phase III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003eCOPD 390M; IBD 7M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235037618441,"sku":"tbph-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tbph-swot-analysis.webp?v=1785733221","url":"https:\/\/dcfanalyst.com\/products\/tbph-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}